Adragos Pharma Acquires Baccinex, Growing Sterile Manufacturing Services
The transaction reaffirms the CDMO’s interest in growth on a global scale.
Adragos Pharma, a contract development and manufacturing organization (CDMO) based in Germany, has purchased Baccinex, a Swiss-based provider of aseptic fill-finish manufacturing.1 The deal—whose terms remain undisclosed—is expected to boost the CDMO's sterile manufacturing offerings, while also representing growth on a global scale.
Baccinex’s experience in the sterile fill-finish space dates back over 20 years, specifically pertaining to processes surrounding liquid and lyophilized vials. The company’s plant is both FDA-certified and EU-GMP certified, offering clinical trial supply, along with small-to-medium scale commercial production.
“Joining Adragos Pharma marks a new chapter for Baccinex. Our shared commitment to quality, innovation, and customer-centric solutions creates an exciting synergy that will enable us to deliver even greater value to our clients worldwide,” said Dr. Ursula Bausch, founder and CEO of Baccinex.
Adrago also appreciates the opportunity to grow its preence in the pharma manufacturing sector.
“The acquisition of Baccinex represents a significant milestone for Adragos,” noted Dr. Andreas Raabe, the company’s founder and CEO. “Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply. This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing.”
In other Adrago news, earlier this month, the CDMO unveiled its ampoule filling line at its Livron facility in France.2 The new line represents a step toward not only enhancing production capacity, but in boosting quality and compliance.
As a result of the new line, ampoule production capacity will not rise to over 160 million ampoules annually, and fill volumes will range from 1 ml to 20 ml.
“We are always attentive to our customers’ needs to better serve their patients. We recognized not only a regulatory demand in Annex 1 but also an urgent need for greater capacity, particularly for larger-volume ampoules,” commented Marco Gorgas, Adrago’s CCO. “That’s why we installed this fourth line, allowing us to offer a capacity of over 160 million ampoules, including options up to 20 ml, tailored to serve our clients’ evolving requirements.”
References
1. Adragos Pharma Acquires Baccinex – A Leading Swiss Sterile Fill-Finish Expert. Adragos Pharma. November 25, 2024. Accessed November 29, 2024. https://adragos-pharma.com/adragos-pharma-acquires-baccinex-a-leading-swiss-sterile-fill-finish-expert/
2. Project Future: We launched our new production line in our Livron facility! Adragos Pharma. November 7, 2024. Accessed November 27, 2024. https://adragos-pharma.com/project-future-we-launched-our-new-production-line-in-our-livron-facility/
